Drugs / IDN 5404
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02582827 | Nov 2017 → Aug 2019 | neoplastic disease or syndrome | NantBioScience, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IDN 5404 | “ABI-011 is a novel, albumin-bound formulation of a potent thiocolchicine analog, IDN 5404, with a mean particle size of approximately 100 nm.” NCT02582827 ↗ |
| Action | Inhibit | “an inhibitor of topoisomerase I” NCT02582827 ↗ |
| Modality | Small molecule | “potent thiocolchicine analog” NCT02582827 ↗ |
| Route | Intravenous | “administered via IV infusion” NCT02582827 ↗ |